Paul P Cook
Overview
Explore the profile of Paul P Cook including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
345
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, et al.
Infect Dis Ther
. 2024 Aug;
13(10):2209-2210.
PMID: 39212853
No abstract available.
2.
Bauer A, Williams J, Pokhrel L, Garcia S, Majumdar N, Eells J, et al.
Toxics
. 2024 Jul;
12(7).
PMID: 39058147
Smart Nano-enabled Antiviral Therapeutic (SNAT) is a promising nanodrug that previously demonstrated efficacy in preclinical studies to alleviate SARS-CoV-2 pathology in hamsters. SNAT comprises taxoid (Tx)-decorated amino (NH)-functionalized near-atomic size...
3.
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, et al.
Infect Dis Ther
. 2024 Jun;
13(10):2105-2121.
PMID: 38941068
Introduction: Recurrent Clostridioides difficile infection (rCDI) often occurs after standard-of-care antibiotics. VOWST oral spores (VOS, previously SER-109), an FDA-approved orally administered microbiome therapeutic, is indicated to prevent rCDI following antibiotics...
4.
Bauer A, Majumdar N, Williams F, Rajput S, Pokhrel L, Cook P, et al.
Biology (Basel)
. 2023 Oct;
12(10).
PMID: 37887044
Since the discovery of microRNAs (miRNAs) in C. elegans in 1993, the field of miRNA research has grown steeply. These single-stranded non-coding RNA molecules canonically work at the post-transcriptional phase...
5.
Akula S, Williams J, Pokhrel L, Bauer A, Rajput S, Cook P
Viruses
. 2022 Dec;
14(12).
PMID: 36560686
Wide variability exists with host response to SARS-CoV-2 infection among individuals. Circulatory micro RNAs (miRNAs) are being recognized as promising biomarkers for complex traits, including viral pathogenesis. We hypothesized that...
6.
Jones R, Smith P, Berg P, de la Pena A, Cook P, Shawa I, et al.
Clin Med Insights Circ Respir Pulm Med
. 2022 Dec;
16:11795484221127555.
PMID: 36531909
[This corrects the article DOI: 10.1177/11795484221119316.].
7.
Jones R, Smith P, Berg P, de la Pena A, Cook P, Shawa I, et al.
Clin Med Insights Circ Respir Pulm Med
. 2022 Aug;
16:11795484221119316.
PMID: 35991210
Background: Severe cases of coronavirus disease 2019 (COVID-19) are characterized by progressive respiratory failure and the development of acute respiratory distress syndrome (ARDS), with high mortality rates for patients requiring...
8.
Pokhrel L, Williams F, Cook P, ORourke D, Murray G, Akula S
Drug Deliv Transl Res
. 2022 Apr;
12(12):3007-3016.
PMID: 35441321
To address the unprecedented global public health crisis due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we designed and developed a novel antiviral nano-drug, called SNAT (Smart Nano-Enabled Antiviral...
9.
Akula S, Bolin P, Cook P
RNA Biol
. 2021 Dec;
19(1):1-11.
PMID: 34904915
The role for circulating miRNAs as biomarkers of the COVID-19 disease remains uncertain. We analysed the circulating miRNA profile in twelve COVID-19 patients with moderate-severe disease. This analysis was conducted...
10.
Pona A, Jiwani R, Afriyie F, Labbe J, Cook P, Mao Y
Dermatol Ther
. 2020 Jul;
33(6):e13930.
PMID: 32602610
No abstract available.